CAJ | 학술논문

目的：分析B细胞血液肿瘤外周血淋巴细胞CD40、CD154表达率的特点。方法28例B细胞血液肿瘤患者分为多发性骨髓瘤（Multiple Myeloma，MM）17例，B细胞性非霍奇金淋巴瘤（B-NHL）11例；选取30例健康体检人员作为对照组。应用流式细胞术检测B细胞血液肿瘤患者外周血淋巴细胞（Peripheral Blood Lymphocytes，PBL）CD40、CD154的表达率。结果①MM组：CD40表达率为（17.50±8.32）%，CD154表达率为（1.00±3.26）%；B-NHL组：CD40表达率为（29.84±15.61）%，CD154表达率为（2.01±0.59）%；对照组：CD40表达率为（6.48±3.34）%，CD154表达率为（3.25±1.04）%。②化疗后B-NHL患者外周血淋巴细胞CD40表达低于化疗前,P<0.05。③MM患者III期组PBLCD40表达率高于I~II期组,P<0.05。 B-NHL患者PBL CD154表达率III~IV期低于I~II期组,P<0.05。结论①MM患者、B-NHL患者均存在PBL CD40高表达，B-NHL患者同时存在PBL CD154低表达；CD40高表达提示MM预后差，CD154低表达与B-NHL预后有关。②化疗降低了B-NHL患者PBL CD40表达率。为临床上进行B细胞血液肿瘤诊断与治疗提供一定的依据。
목적：분석B세포혈액종류외주혈림파세포CD40、CD154표체솔적특점。방법28례B세포혈액종류환자분위다발성골수류（Multiple Myeloma，MM）17례，B세포성비곽기금림파류（B-NHL）11례；선취30례건강체검인원작위대조조。응용류식세포술검측B세포혈액종류환자외주혈림파세포（Peripheral Blood Lymphocytes，PBL）CD40、CD154적표체솔。결과①MM조：CD40표체솔위（17.50±8.32）%，CD154표체솔위（1.00±3.26）%；B-NHL조：CD40표체솔위（29.84±15.61）%，CD154표체솔위（2.01±0.59）%；대조조：CD40표체솔위（6.48±3.34）%，CD154표체솔위（3.25±1.04）%。②화료후B-NHL환자외주혈림파세포CD40표체저우화료전,P<0.05。③MM환자III기조PBLCD40표체솔고우I~II기조,P<0.05。 B-NHL환자PBL CD154표체솔III~IV기저우I~II기조,P<0.05。결론①MM환자、B-NHL환자균존재PBL CD40고표체，B-NHL환자동시존재PBL CD154저표체；CD40고표체제시MM예후차，CD154저표체여B-NHL예후유관。②화료강저료B-NHL환자PBL CD40표체솔。위림상상진행B세포혈액종류진단여치료제공일정적의거。
Objective To analyze the characteristics of expression rate of peripheral blood lymphocytes (PBL) CD40 and CD154 in patients with B-cell hematologic malignancies. Methods 28 cases of patients with B-cell hematologic malignancies were divided into 17 cases with multiple myelom (MM) and 11 cases with B-cell non-Hodgkin's lymphoma (B-NHL); 30 healthy people underwent healthy examination were selected as the control group. Flow cytometry was used to detect the expression rate of PBL CD40 and CD154 of patients with B-cell hematologic malignancies. Results 1. MM group: the expression rate of CD40 was (17.50 ± 8.32)%, and that of CD154 was (1.00 ± 3.26)%; B-NHL group: the expression rate of CD40 was (29.84 ± 15.61)%, and that of CD154 was (2.01 ± 0.59)%; Control group: the expression rate of CD40 was (6.48 ± 3.34)%, and that of CD154 was (3.25 ± 1.04)%. 2.The expression rate of PBL CD40 of B-NHL patients after chemotherapy was lower than that before chemotherapy, P<0.05. 3.PBL CD40 expression rate of stage III subgroup in MM group was higher than that of stage I and stage II subgroups, P<0.05. PBL CD154 expression rate of stage III and IV subgroups in B-NHL group was lower than that of stage I and II subgroup, P<0.05. Conclusion 1. Patients with MM and patients with B-NHL had high expression of PBL CD40, and B-NHL patients also had low expression of PBL CD154; high expression of CD40 was associated with poor prognosis in patients with MM; low expression of CD154 was associated with poor prognosis in patients with B-NHL. 2. Chemotherapy reduced the expression rate of PBL CD40 in patients with B-NHL. It provides a basis for the diagnosis and treatment of B-cell hematologic malignancies.